Atossa Therapeutics (ATOS) is a pre-revenue clinical-stage pharmaceutical company with zero product sales and an accumulated deficit of $256.2 million as of March 31, 2026. Under a liquidation lens, the recovery posture is structurally thin but nominally positive at the balance-sheet level, driven almost entirely by cash. Total assets of $37.9 million consist of cash and cash equivalents of $31.7 million (recoverable at 100%), restricted cash of $0.11 million, prepaid and other current assets of $1.8 million (recoverable at roughly 80-90% haircut, yielding ~$1.5 million), and non-current assets of $1.3 million (primarily Australian R&D tax rebate receivable and security deposits, which carry meaningful collection risk). PP&E is de minimis ($4K depreciation, zero capex). All intangibles and pipeline value are zero in liquidation. Applying standard haircuts, estimated liquidation value of assets is approximately $32-33 million. Total liabilities are $7.5 million, all current, consisting of accounts payable ($2.6 million), accrued liabilities ($2.8 million), employee liabilities ($0.9 million), other current liabilities ($1.1 million, which includes the $1.1 million ATO tax accrual disclosed in the risk factors), and other smaller accruals. No funded debt, no pension, no long-term lease obligations appear on the balance sheet. Estimated net liquidation recovery to equity is therefore in the range of $24-26 million, broadly consistent with the MFFAIS CLV/LLV/OLV of $24.3 million. The primary risk to this estimate is the $5.3 million non-cancellable CRO contract commitment disclosed in MD&A, which would constitute a liquidation liability not separately tagged in XBRL. If treated at face value, this reduces recovery by approximately $5 million, bringing estimated equity recovery to roughly $19-21 million. The company has formally disclosed going concern doubt. Operating cash burn accelerated materially: $9.6 million consumed in Q1 2026 versus $6.0 million in Q1 2025, a 61% year-over-year increase, driven by higher clinical trial spend (+$2.4 million) and legal/professional fees (+$1.3 million). At Q1 2026 run rate, the current $31.7 million cash balance provides approximately 3.3 quarters of runway with no financing. A $50 million ATM facility with Rodman & Renshaw was established in February 2026 but no sales had occurred as of the filing date. The filing does not separately XBRL-tag the $5.3 million non-cancellable contractual commitment or the $1.1 million ATO tax exposure—both are disclosed in MD&A and risk factors only.
▼ Community Notes